RELATIONSHIP OF CYP2D6 GENETIC POLYMORPHISMS AND THE PHARMACOKINETICS OF TRAMADOL IN CHINESE VOLUNTEERS

被引：0
|
作者：
Li, Qin [1 ]
Zhong, Dafang [2 ]
Lou, Jianshi [1 ]
Wang, Rui [3 ]
机构：
[1] Tianjin Med Univ, Dept Pharmacol, Tianjin 300070, Peoples R China
[2] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Metab & Pharmacokinet Res, Shanghai 200031, Peoples R China
[3] Chinese People Liberat Army Gen Hosp, Dept Clin Pharmacol, Beijing 100853, Peoples R China
来源：
DRUG METABOLISM REVIEWS | 2008年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
60
引用
下载
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [21] Influence of CYP2D6 gene polymorphisms on the pharmacokinetics of aripiprazole in healthy Chinese subjects
    Zhang, Xiaodan
    Liu, Chengquan
    Zhou, Shuang
    Xie, Ran
    He, Xu
    Wang, Zhiqi
    Yi, Honghong
    Shu, You
    Wang, Zining
    Hu, Kun
    Ma, Lingyue
    Cui, Yimin
    Zhao, Xia
    Xiang, Jin
    PHARMACOGENOMICS, 2021, 22 (04) : 213 - 223
  • [22] Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
    O. Spigset
    K. Granberg
    S. Hägg
    Å. Norström
    R. Dahlqvist
    European Journal of Clinical Pharmacology, 1997, 52 : 129 - 133
  • [23] Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
    Spigset, O
    Granberg, K
    Hagg, S
    Norstrom, A
    Dahlqvist, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) : 129 - 133
  • [24] CYP2D6*10 POLYMORPHISM DOES NOT INFLUENCE TRAMADOL PHARMACOKINETICS IN CHINESE HEALTHY SUBJECTS.
    Zhang, L.
    Jiao, Z.
    Li, Z.
    Shi, X.
    Zhong, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S52 - S52
  • [25] Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers
    Gasso, Patricia
    Papagianni, Katerina
    Mas, Sergi
    Fernandez de Bobadilla, Ramon
    Albert Arnaiz, Joan
    Bernardo, Miquel
    Lafuente, Amalia
    PHARMACOGENOMICS, 2013, 14 (13) : 1551 - 1563
  • [26] RELATIONSHIP BETWEEN CYP2D6 GENOTYPE AND HALOPERIDOL PHARMACOKINETICS AND EXTRAPYRAMIDAL SYMPTOMS IN HEALTHY VOLUNTEERS
    Lafuente, A.
    Gasso, P.
    Papagianni, K.
    Mas, S.
    Fernandez de Bobadilla, R.
    Arnaiz, J. A.
    Bernardo, M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 52 - 52
  • [27] Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers
    Pawlowska, M.
    Bogiel, M.
    Duda, J.
    Sieradzki, E.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 71 (06) : 699 - 705
  • [28] Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers
    M. Pawlowska
    M. Bogiel
    J. Duda
    E. Sieradzki
    European Journal of Clinical Pharmacology, 2015, 71 : 699 - 705
  • [29] Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects
    Gan, SH
    Ismail, R
    Adnan, WAW
    Wan, Z
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (02) : 189 - 195
  • [30] The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects
    Xiujun Wu
    Li Yuan
    Jinliang Zuo
    Jing Lv
    Tao Guo
    European Journal of Clinical Pharmacology, 2014, 70 : 57 - 63
12345